HiChIP-based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 that Confers Genetic Susceptibility to Gastroesophageal Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 May 2024
Historique:
accepted: 08 05 2024
received: 09 08 2023
revised: 01 02 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

Genome-wide association studies (GWAS) have identified more than a hundred single nucleotide variants (SNVs) associated with the risk of gastroesophageal cancer (GEC). The majority of the identified SNVs map to noncoding regions of the genome. Uncovering the causal SNVs and the genes they modulate could help improve GEC prevention and treatment. Here, we used HiChIP against histone 3 lysine 27 acetylation (H3K27ac) to simultaneously annotate active promoters and enhancers, identify the interactions between them, and detect nucleosome free regions (NFRs) harboring potential causal SNVs in a single assay. Application of H3K27Ac HiChIP in GEC relevant models identified 61 potential functional SNVs that reside in NFRs and interact with 49 genes at 17 loci. The approach led to a 67% reduction in the number of SNVs in linkage disequilibrium at these 17 loci, and at seven loci a single putative causal SNV was identified. One SNV, rs147518036, located within the promoter of the UDP-glucuronate decarboxylase 1 (UXS1) gene appeared to underlie the GEC risk association captured by the rs75460256 index SNV. The rs147518036 SNV creates a GABPA DNA recognition motif, resulting in increased promoter activity, and CRISPR-mediated inhibition of the UXS1 promoter reduced viability of GEC cells. These findings provide a framework that simplifies the identification of potentially functional regulatory SNVs and target genes underlying risk-associated loci. In addition, the study implicates increased expression of the enzyme UXS1 and activation of its metabolic pathway as a predisposition to gastric cancer, which highlights potential therapeutic avenues to treat this disease.

Identifiants

pubmed: 38748784
pii: 745368
doi: 10.1158/0008-5472.CAN-23-2397
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Ansley Gnanapragasam (A)

McGill University, Montreal, Quebec, Canada.

Eftyhios Kirbizakis (E)

McGill University, Montreal, Quebec, Canada.

Anna Li (A)

McGill University Health Centre, Montreal, Quebec, Canada.

Kyle H White (KH)

McGill University, Montreal, Quebec, Canada.

Katelyn L Mortenson (KL)

Huntsman Cancer Institute, United States.

Juliana Cavalcante de Moura (J)

McGill University Health Centre, Montreal, Quebec, Canada.

Wajih Jawhar (W)

McGill University, Montreal, QC, Canada.

Yifei Yan (Y)

McGill University Health Centre, Montreal, Quebec, Canada.

Reilly Falter (R)

Huntsman Cancer Institute, Salt Lake City, Utah, United States.

Colleen Russett (C)

McGill University, Montreal, Quebec, Canada.

Betty Giannias (B)

McGill University, Montreal, Quebec, Canada.

Nicholas Bertos (N)

Research Institute of the McGill University Health Centre, Montreal, QC, Canada.

Jonathan Cools-Lartigue (J)

McGill University, Montreal, QC, Canada.

Livia Garzia (L)

McGill University, Montreal, QC, Canada.

Veena Sangwan (V)

McGill University, Montreal, QC, Canada.

Lorenzo E Ferri (LE)

McGill University, Montreal, Quebec, Canada.

Xiaoyang Zhang (X)

Huntsman Cancer Institute, Salt Lake City, Utah, United States.

Swneke D Bailey (SD)

McGill University, Montreal, Quebec, Canada.

Classifications MeSH